The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial What we learn from subgroup analyses

被引：55

作者：

Ginsberg, Henry N. ^{[1
,2
]}

机构：

[1] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10027 USA

[2] Columbia Univ, Coll Phys & Surg, Irving Inst Clin & Translat Res, New York, NY USA

来源：

DIABETES CARE | 2011年 / 34卷

关键词：

CORONARY-HEART-DISEASE; LDL CHOLESTEROL; INTERVENTION; MEN; GEMFIBROZIL; PREVENTION; MORTALITY; THERAPY; PEOPLE;

D O I：

10.2337/dc11-s203

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S107 / S108

页数：2

共 14 条

[1] Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and methods [J].

Buse, John B. .

AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A) :21I-33I

[2] Diabetic dyslipidemia [J].

Chahil, Tina J. ;

Ginsberg, Henry N. .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2006, 35 (03) :491-+

[3]

Collins R, 2003, LANCET, V361, P2005

[4] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[5]

Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282

[6] Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J].

Haffner, SM ;

Lehto, S ;

Rönnemaa, T ;

Pyörälä, K ;

Laakso, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :229-234

[7] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[8] JOINT EFFECTS OF SERUM TRIGLYCERIDE AND LDL CHOLESTEROL AND HDL CHOLESTEROL CONCENTRATIONS ON CORONARY HEART-DISEASE RISK IN THE HELSINKI HEART-STUDY - IMPLICATIONS FOR TREATMENT [J].

MANNINEN, V ;

TENKANEN, L ;

KOSKINEN, P ;

HUTTUNEN, JK ;

MANTTARI, M ;

HEINONEN, OP ;

FRICK, MH .

CIRCULATION, 1992, 85 (01) :37-45

[9] Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Nelson, DB ;

Elam, MB ;

Schaefer, EJ ;

Faas, FH ;

Anderson, JW .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (22) :2597-2604

[10] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Fye, CL ;

Anderson, JW ;

Elam, MB ;

Faas, FH ;

Linares, E ;

Schaefer, EJ ;

Schectman, G ;

Wilt, TJ ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :410-418

← 1 2 →